Stock Financial Ratios, Dividends, Split History
TRNS / Transcat, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||163.38|
|Book Value ($M)||48.60|
|Book Value / Share||6.80|
|Price / Book||3.18|
|NCAV / Share||-1.22|
|Price / NCAV||-32.93|
|Weighted Average Number Of Diluted Shares Outstanding||7,303,000|
|Weighted Average Number Diluted Shares Outstanding Adjustment||179,000|
|Weighted Average Number Of Shares Outstanding Basic||7,124,000|
|Common Stock Shares Outstanding||7,155,050|
|Common Shares Outstanding||7,197,513|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.06|
|Return on Assets (ROA)||0.06|
|Return on Equity (ROE)||0.12|
|Identifiers and Descriptors|
|Central Index Key (CIK)||99302|
Stock splits are used by Transcat, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Badger Meter, Inc. (BMI - Free Report) reported promising results for the second-quarter 2018. The company registered both record revenues and adjusted earnings, driven by higher domestic municipal sales of its flagship products and increased international sales, notably in the Middle East. Net Income On a GAAP basis, net income for the reported quarter came in at $6.2 million or 21 cents per share compared with $10.
At Singular Research, we focus on small to micro cap companies that lack analyst coverage and have a compelling investment story. It is only a matter of time before these companies are discovered leading to broader institutional coverage and potentially dynamic returns. We want you to be invested in these companies before the stock market and other analysts realize their true potential. Over the last 14 years, our coverage has outperformed our competition and the Russell 2000 by a wide and consistent margin. (1-0)
Greetings, and welcome to the Transcat, Inc. Fourth Quarter and Full Fiscal Year 2018 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operation Instructions] As a reminder, this conference is being recorded.
The following slide deck was published by Transcat, Inc. in conjunction with their 2018 Q4 earnings call.
Woodward, Inc. (WWD - Free Report) reported second-quarter fiscal 2018 adjusted earnings of 82 cents per share, which surpassed the Zacks Consensus Estimate of 79 cents by 3.8%. Adjusted earnings included a one-time expense of 22 cents per share, courtesy of the pre-tax restructuring charges. Excluding the one-time adjustments, the company reported GAAP earnings of 60 cents per share, which came in line with the year-ago quarter’s figure. (2-0)
as of ET